China Pharma Holdings (CPHI) Liabilities and Shareholders Equity (2010 - 2026)

China Pharma Holdings' Liabilities and Shareholders Equity history runs 17 years deep, the most recent figure standing at $45.1 million for Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 217.53% year-over-year to $45.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $105.7 million (up 86.01% YoY) and the FY2025 annual result came in at $31.0 million, up 108.22% from the prior year.
• Liabilities and Shareholders Equity was $45.1 million for Q1 2026 at China Pharma Holdings, up from $31.0 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $45.1 million in Q1 2026 and bottomed at $13.5 million in Q3 2024.
• A 5-year average of $18.6 million and a median of $16.2 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity fell 21.48% — and 2026, when it soared 217.53%.
• China Pharma Holdings' Liabilities and Shareholders Equity stood at $17.8 million in 2022, then retreated by 7.39% to $16.5 million in 2023, then dropped by 9.6% to $14.9 million in 2024, then surged by 108.22% to $31.0 million in 2025, then surged by 45.63% to $45.1 million in 2026.
• Business Quant data shows CPHI's Liabilities and Shareholders Equity at $45.1 million in Q1 2026, $31.0 million in Q4 2025, and $15.8 million in Q3 2025.